|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Alaunos_Therapeutics
|
|
gptkbp:advertising
|
global expansion
partnerships with pharmaceutical companies
collaborations with research institutions
focus on mRNA technology
|
|
gptkbp:CEO
|
gptkb:Franz-Werner_Haas
|
|
gptkbp:clinicalTrials
|
gptkb:COVID-19_vaccine
Phase 1
Phase 2
Phase 3
therapeutic vaccines
cancer vaccine trials
infectious disease trials
prophylactic vaccines
COVID-19_vaccine_trials
|
|
gptkbp:collaborations
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Max_Planck_Institute
gptkb:European_Commission
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:University_of_California
gptkb:University_of_Cambridge
gptkb:University_of_Michigan
gptkb:University_of_Pennsylvania
gptkb:University_of_Toronto
gptkb:Karolinska_Institute
gptkb:ETH_Zurich
gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI)
|
|
gptkbp:employeeCount
|
over 300
|
|
gptkbp:focus
|
mRNA technology
|
|
gptkbp:founded
|
2000
|
|
gptkbp:founder
|
gptkb:Ingmar_Hoerr
|
|
gptkbp:funding
|
venture capital
government grants
private investments
public offerings
|
|
gptkbp:headquarters
|
gptkb:Tübingen,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CureVac N.V.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
$100 million
|
|
gptkbp:market
|
global
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:AstraZeneca
gptkb:Bayer_AG
|
|
gptkbp:patentCitation
|
lipid nanoparticles
mRNA delivery systems
RNA modification technologies
|
|
gptkbp:products
|
CVnCoV
|
|
gptkbp:regulatoryCompliance
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:research_focus
|
infectious diseases
cancer vaccines
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
gptkb:CureVac_AG
CureVac_Biologics
CureVac_RNA_Technologies
|
|
gptkbp:technology
|
mRNA therapeutics
RNA-based vaccines
mRNA cancer therapies
|